Scientific References
Use of supplements in the prevention and treatment of Alzheimer's Disease
A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease; Mary Sano, Ph.D., Christopher Ernesto, M.S., Ronald G. Thomas, Ph.D., Melville R. Klauber, Ph.D., Kimberly Schafer, M.S., Michael Grundman, M.D., M.P.H., Peter Woodbury, John Growdon, M.D., Carl W. Cotman, Ph.D., Eric Pfeiffer, M.D., Lon S. Schneider, M.D., and Leon J. Thal, M.D. for the Members of the Alzheimer's Disease Cooperative Study; N Engl J Med 1997; 336:1216-1222 April 24, 1997
Omega Fatty Acid, Vitamins and Alzheimer's Disease
Plasma Phosphatidylcholine Docosahexaenoic Acid Content and Risk of Dementia and Alzheimer Disease: The Framingham Heart Study Ernst J. Schaefer, MD; Vanina Bongard, MD, PhD; Alexa S. Beiser, PhD; Stefania Lamon-Fava, MD, PhD; Sander J. Robins, MD; Rhoda Au, PhD; Katherine L. Tucker, PhD; David J. Kyle, PhD; Peter W. F. Wilson, MD; Philip A. Wolf, MD, Arch Neurol. 2006;63:1545-1550.
The molecular bases of Alzheimer's disease and other neurodegenerative disorders. Maccioni RB, Munoz JP, Barbeito L. Arch Med Res. 2001;32(5):367-381.
[Abstract]
Dietary intake of fatty acids and fish in relation to cognitive performance at middle age. Kalmijn S, van Boxtel MP, Ocke M, Verschuren WM, Kromhout D, Launer LJ. Neurology. 2004;62(2):275-280.
[Abstract]
Dietary fat intake and the risk of incident dementia in the Rotterdam Study. Kalmijn S, Launer LJ, Ott A, Witteman JC, Hofman A, Breteler MM. Ann Neurol. 1997;42(5):776-782.
[Abstract]
Fatty acids, lipid metabolism and Alzheimer pathology. Hooijmans CR, Kiliaan AJ. Eur J Pharmacol. 2008;585(1):176-196.
[Abstract]
DHA (Docosahexaenoic Acid), an Omega 3 Fatty Acid, in Slowing the Progression of Alzheimer's Disease. National Institutes of Health. ClinicalTrials.
[Web page].
Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Morris MC, Evans DA, Bienias JL, et al. Arch Neurol. 2003;60(7):940-946.
[Abstract]
Current and future therapy in Alzheimer's disease. van Marum RJ. Fundam Clin Pharmacol. 2008;22(3):265-274.
[Abstract]
Low serum docosahexaenoic acid is a significant risk factor for Alzheimer's dementia. Kyle DJ, Schaefer E, Patton G, Beiser A. Lipids. 1999;34 Suppl:S245.
[Abstract]
Fatty acid analysis of blood plasma of patients with Alzheimer's disease, other types of dementia, and cognitive impairment. Conquer JA, Tierney MC, Zecevic J, Bettger WJ, Fisher RH. Lipids. 2000;35(12):1305-1312.
[Abstract]
Low serum cholesteryl ester-docosahexaenoic acid levels in Alzheimer's disease: a case-control study. Tully AM, Roche HM, Doyle R, et al. Br J Nutr. 2003;89(4):483-489.
[Abstract]
Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study. Schaefer EJ, Bongard V, Beiser AS, et al. Arch Neurol. 2006;63(11):1545-1550.
[Abstract]
Ginkgo biloba and Alzheimer's Disease
Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo-controlled double-blind study. Mazza M, Capuano A, Bria P, et al. Eur J Neurol 2006 Sep;13(9):981-5.
Ginkgo biloba for acute ischaemic stroke. Zeng X, Liu M, Yang Y, et al. Cochrane Database Syst Rev 2005 Oct 19;(4):CD003691.
Ginkgo biloba for cognitive impairment and dementia. Birks J, Grimley Evans J. Cochrane Database Syst Rev 2007 Apr 18;(2):CD003120.
Ginkgo biloba for prevention of dementia: a randomized controlled trial. DeKosky ST, Williamson JD, Fitzpatrick AL, et al. Journal of the American Medical Association. 2008;300(19):2253–2262.
